Please assess the completion status of the following clinical trial:

Trial Title: Topical 5% Imiquimod Cream for Vulvar Paget's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-invasive vulvar Paget's disease, primary or recurrence after earlier surgery;~* Willing and able to comply with the protocol and to provide informed consent in accordance with institutional and regulatory guidelines.~Exclusion Criteria:~* Invasive vulvar Paget's disease;~* Underlying adenocarcinoma;~* Treatment of the vulva with topical 5% imiquimod cream during the last 6 months;~* Participation in a study with another investigational product within 30 days prior to enrolment in this study;~* Hypersensitivity to any component of topical 5% imiquimod cream (methylhydroxybenzoate (E218), propylhydroxybenzoate (E216), cetylalcohol, atearylalcohol);~* Patients with autoimmune disorders;~* Immune compromised patients (e.g. HIV patients, patients with a history of transplantation);~* Insufficient understanding of the Dutch or English language;~* Pregnant women;~* Lactating women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Imiquimod (Type: EXPERIMENTAL): Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).